» Articles » PMID: 35468331

Risk of Hospitalisation Associated with Infection with SARS-CoV-2 Omicron Variant Versus Delta Variant in Denmark: an Observational Cohort Study

Abstract

Background: Estimates of the severity of the SARS-CoV-2 omicron variant (B.1.1.529) are crucial to assess the public health impact associated with its rapid global dissemination. We estimated the risk of SARS-CoV-2-related hospitalisations after infection with omicron compared with the delta variant (B.1.617.2) in Denmark, a country with high mRNA vaccination coverage and extensive free-of-charge PCR testing capacity.

Methods: In this observational cohort study, we included all RT-PCR-confirmed cases of SARS-CoV-2 infection in Denmark, with samples taken between Nov 21 (date of first omicron-positive sample) and Dec 19, 2021. Individuals were identified in the national COVID-19 surveillance system database, which included results of a variant-specific RT-PCR that detected omicron cases, and data on SARS-CoV-2-related hospitalisations (primary outcome of the study). We calculated the risk ratio (RR) of hospitalisation after infection with omicron compared with delta, overall and stratified by vaccination status, in a Poisson regression model with robust SEs, adjusted a priori for reinfection status, sex, age, region, comorbidities, and time period.

Findings: Between Nov 21 and Dec 19, 2021, among the 188 980 individuals with SARS-CoV-2 infection, 38 669 (20·5%) had the omicron variant. SARS-CoV-2-related hospitalisations and omicron cases increased during the study period. Overall, 124 313 (65·8%) of 188 980 individuals were vaccinated, and vaccination was associated with a lower risk of hospitalisation (adjusted RR 0·24, 95% CI 0·22-0·26) compared with cases with no doses or only one dose of vaccine. Compared with delta infection, omicron infection was associated with an adjusted RR of hospitalisation of 0·64 (95% CI 0·56-0·75; 222 [0·6%] of 38 669 omicron cases admitted to hospital vs 2213 [1·5%] of 150 311 delta cases). For a similar comparison by vaccination status, the RR of hospitalisation was 0·57 (0·44-0·75) among cases with no or only one dose of vaccine, 0·71 (0·60-0·86) among those who received two doses, and 0·50 (0·32-0·76) among those who received three doses.

Interpretation: We found a significantly lower risk of hospitalisation with omicron infection compared with delta infection among both vaccinated and unvaccinated individuals, suggesting an inherent reduced severity of omicron. Our results could guide modelling of the effect of the ongoing global omicron wave and thus health-care system preparedness.

Funding: None.

Citing Articles

SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.

Alhamlan F, Al-Qahtani A Int J Mol Sci. 2025; 26(3).

PMID: 39941026 PMC: 11818319. DOI: 10.3390/ijms26031263.


Effectiveness of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2.2 Infection in Beijing, China, 2022: A Cohabitation Retrospective Cohort Study.

Dong S, Sun Y, Feng Z, Tian Y, Jia L, Wang X Viruses. 2025; 17(1).

PMID: 39861820 PMC: 11769300. DOI: 10.3390/v17010031.


Insights into Omicron: Genomic Characterization and Inpatient Risk Assessment at Single Tertiary Hospital in Indonesia.

Turbawaty D, Komala D, Andriyoko B J Multidiscip Healthc. 2025; 18():71-81.

PMID: 39816439 PMC: 11733193. DOI: 10.2147/JMDH.S486098.


Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures.

Gonzalez-Carmona M, Schmitz A, Berger M, Baier L, Gorny J, Sadeghlar F Int J Mol Sci. 2025; 25(24.

PMID: 39769379 PMC: 11728159. DOI: 10.3390/ijms252413613.


Risk factors for COVID-19 pneumonia in patients with hematological malignancies: a multi-center, prospective study in China.

Li J, Chen R, Cao L, Liu Y, Zhang Y, Wei X Front Immunol. 2024; 15:1408969.

PMID: 39575255 PMC: 11578944. DOI: 10.3389/fimmu.2024.1408969.


References
1.
Veneti L, Boas H, Kristoffersen A, Stalcrantz J, Bragstad K, Hungnes O . Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022; 27(4). PMC: 8796289. DOI: 10.2807/1560-7917.ES.2022.27.4.2200077. View

2.
Spiegelman D, Hertzmark E . Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005; 162(3):199-200. DOI: 10.1093/aje/kwi188. View

3.
Hussey H, Davies M, Heekes A, Williamson C, Valley-Omar Z, Hardie D . Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections - a survival analysis. Int J Infect Dis. 2022; 118:150-154. PMC: 8882068. DOI: 10.1016/j.ijid.2022.02.051. View

4.
Espenhain L, Funk T, Overvad M, Edslev S, Fonager J, Ingham A . Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Euro Surveill. 2021; 26(50). PMC: 8728489. DOI: 10.2807/1560-7917.ES.2021.26.50.2101146. View

5.
Ulloa A, Buchan S, Daneman N, Brown K . Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. JAMA. 2022; 327(13):1286-1288. PMC: 8855311. DOI: 10.1001/jama.2022.2274. View